Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings

The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news